Showing results (2151-2160 of 3,833) with videos related to

Sort By:
Pageof 384
The Japanese Journal of Antibiotics|March 1, 1976
[Clinical experience with gentamicin in complicated urinary tract infections (author's transl)]K Mitobe, H Tanda, T Aoyama, et al.
The Japanese Journal of Antibiotics|May 2, 2003
[Successful combination therapy of teicoplanin with cefmetazole on postoperative cardiovascular MRSA infections: clinical report on two cases]Yoshihito Otsuka, Yukio Shimamura, Takako Yoshibe, et al.
The Japanese Journal of Antibiotics|December 1, 1992
[Clinical studies on cefprozil granules in pediatric skin soft tissues infections]T Motohiro, M Aramaki, K Oda, et al.
The Japanese Journal of Antibiotics|December 1, 1992
[Pharmacokinetic and clinical studies of cefprozil fine granules in children]K Nagano, H Maeda, T Yanagi, et al.
The Japanese Journal of Antibiotics|March 1, 1976
[Further study on gentamicin in pediatrics (author's transl)]S Nakazawa, H Sato, O Watanabe, et al.
The Japanese Journal of Antibiotics|October 22, 2003
[Recent findings based on the results of the post-marketing surveillance of vancomycin hydrochloride for intravenous infusion]Kaoru Shimada
The Japanese Journal of Antibiotics|October 22, 2003
[Clinical efficacy and bacteriological studies of clarithromycin and cefdinir against group A beta-hemolytic streptococcal tonsillopharyngitis]Tadafumi Nishimura, Kumiko Sugita, Kyouji Taniguchi, et al.
The Japanese Journal of Antibiotics|October 22, 2003
[The effect of intravenous ciprofloxacin for community acquired pneumonia in adults]Masaki Fujita, Tsuneo Ishibashi, Nobuyuki Hara, et al.
The Japanese Journal of Antibiotics|December 25, 2003
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2001). I. Susceptibility distribution]Yoshiaki Kumamoto, Taiji Tsukamoto, Kiyoaki Watanabe, et al.
The Japanese Journal of Antibiotics|December 25, 2003
[Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria]Jun Igari, Toyoko Oguri, Nobuyoshi Hiramatsu, et al.
Pageof 384